Overview

KW-3357 Study in Patients With Early Onset Severe Preeclampsia

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of intravenous KW-3357 in patients with early-onset severe preeclampsia by comparing the prolongation days of pregnancy with that of placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Kirin Co., Ltd.
Collaborator:
Japan Blood Products Organization
Treatments:
Antithrombin III
Antithrombins